“The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are poised to start our registrational upLIFT study for tumor HI mid-year,” said Nevan Charles Elam, CEO and founder of Rezolute (RZLT). “Each of our programs received Breakthrough Therapy Designation from FDA this year. We look forward to continued discussions with the agency with a focus on treating hypoglycemia caused by all forms of hyperinsulinism with the goal of advancing our novel therapy towards approval and commercialization.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute’s Ersodetug Gains Momentum with Breakthrough Therapy Designation and Promising Market Potential
- Rezolute announces FDA granted BTD to ersodetug
- Rezolute Closes $96.9 Million Underwritten Offering
- Douglas Tsao’s Buy Rating on Rezolute: Strong Financial Position and Promising Pipeline Boost Confidence
- H.C. Wainwright keeps Buy on Rezolute after no changes to sunRIZE sample size